Advertisement


Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

2022 ASH Annual Meeting and Exposition

Advertisement

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The standard of care for multiple myeloma patients with a new diagnosis and for patients that are transplant eligible in Canada, is to first to start with a bortezomib-based induction and then go with a high dose melphalan, an autologous stem cell transplant, followed by lenalidomide maintenance until progression. So, the aim of our study was really to look at the outcomes in details of this patient population in Canada, in the real world setting. So, using our national myeloma database from the C M R G, known as the Canadian Myeloma Research Group, all the patients who received an autologous stem cell transplant for multiple myeloma in the first line setting, from January 2007 to December 2021, were included. So, this gives us 3,800 patients approximately, and most of them received a bortezomib-based induction, mostly being CYBORD, in 72%. We had mostly single-transplant patients. Only 8% received tandem transplant, and it was mostly in high risk patients. 18% of the population were high risk. And what's interesting to see is that, overall with one single transplant, median PFS was around 35 months, and median overall survival was around 10 years. And median overall survival was around 10 years for approximately all subgroup patients, except in high-risk patients; so high-risk patients had inferior outcomes. For consolidation therapy, it's not root routinely available in Canada, so only a few patients received that kind of therapy, about 5%. It was mostly a regimen combining a ubiquitin and a proteasome inhibitor. Globally, consolidation leads to a better PFS, but with no significant gain on OS. For maintenance therapy, about half of our court received maintenance therapy, and it was mostly lenalidomide-based regimen. Maintenance therapy was leading to a significant benefit on PFS and OS, in all risk subgroups, although it does not completely abrogate the negative impact of high risk cytogenetics in the high risk patients. Globally, with the lenalidomide-based maintenance regimen, the PFS was around 4.5 years, and the overall survival around 13 years. As you can see, this real world data covers about 15 years in our court of timeline. And it really shows that the integration of bortezomib and lenalidomide in the transplant sequence, leads to an overall survival of about 10 years in most autologous stem cell transplant patient. It also highlights the beneficial contribution of lenalidomide mainstream therapy in patients without and with high risks, and also in patients receiving a second course of induction. Indeed, these patients had significantly inferior outcomes compared to those receiving only one induction regimen, but with maintenance therapy, outcomes would were comparable even though you received one or two induction regimen. So, this really highlights the importance of maintenance therapy in these subgroups. Right now, further analysis are ongoing, to look at relationship between treatment outcomes, patients characteristics, and these results will really serve as Canadian benchmarks to compare with newer approaches that are eventually coming.

Related Videos

Leukemia
Issues in Oncology

Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends

Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute myeloid leukemia (AML). Between 2000 and 2019, AML mortality was the highest in Whites and the lowest in American Indians or Alaska Natives. The highest rate of increase in mortality was seen in Asians or Pacific Islanders. Dr. Al Armashi talks about the many variables that might contribute to these inequalities (Abstract 600).

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Leukemia
Lymphoma

Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).

Leukemia

Jorge E. Cortes, MD, on CML: Efficacy and Safety of Vodobatinib

Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discusses new findings on vodobatinib, which was administered to patients with chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia (CML) and appeared to be efficacious and safe in people who had received therapy with two or three prior tyrosine kinase inhibitors (TKIs). Vodobatinib remains a potential option for these highly refractory patients. A phase II study (NCT02629692) of vodobatinib is ongoing in CML patients whose disease has failed to respond to three or more TKIs, including ponatinib (Abstract 84).

Hematologic Malignancies
Genomics/Genetics

Smita Bhatia, MD, MPH: Some Clonal Mutations May Predict Therapy-Related Myeloid Neoplasms

Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discusses study findings that showed key somatic mutations in the peripheral blood stem cell product increases the risk of developing therapy-related myeloid neoplasms (Abstract 119).

Advertisement

Advertisement




Advertisement